Mersana Therapeutics Inc 0M4
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 0M4 is a good fit for your portfolio.
News
-
Mersana Therapeutics Shares Rise 8% After FDA Lifts Clinical Hold for Cancer Treatment
-
Mersana Says FDA Lifts Clinical Hold on Gastric-Cancer Treatment Phase I Trial
-
Mersana Therapeutics's stock craters after FDA halts trials of ovarian cancer treatment after patient deaths
-
Mersana Therapeutics Says 2 Drug Trials Put on Partial Hold
Trading Information
- Previous Close Price
- $2.00
- Day Range
- $1.90–1.90
- 52-Week Range
- $0.76–12.30
- Bid/Ask
- $1.90 / $1.97
- Market Cap
- $232.91 Mil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.78
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 123
- Website
- https://www.mersana.com
Comparables
Valuation
|
Metric
|
0M4
|
CLDX
|
NUVL
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 9.44 | 2.72 | 7.43 |
Price/Sales | 6.78 | 293.27 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
0M4
|
CLDX
|
NUVL
|
|---|---|---|---|
Quick Ratio | 3.43 | 31.44 | 20.70 |
Current Ratio | 3.51 | 31.77 | 20.93 |
Interest Coverage | −34.91 | — | — |
Quick Ratio
0M4
CLDX
NUVL
Profitability
|
Metric
|
0M4
|
CLDX
|
NUVL
|
|---|---|---|---|
Return on Assets (Normalized) | −41.22% | −23.59% | −21.42% |
Return on Equity (Normalized) | −196.75% | −25.21% | −22.49% |
Return on Invested Capital (Normalized) | −129.55% | −25.04% | −26.50% |
Return on Assets
0M4
CLDX
NUVL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Kyzpcylb | Ytqfnrf | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Yjczsdtzf | Ghfbhc | $114.2 Bil | |||
| Moderna Inc
MRNA
| Lxhsckyq | Fqml | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Wywqrsf | Kyybc | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Bfjgphxt | Dsn | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Kvwbpwh | Rlqvcl | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Sqlgkqh | Ypvykvf | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Qktgcgmb | Msjgn | $12.8 Bil | |||
| Incyte Corp
INCY
| Flthsbtbp | Xshqpw | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Nnhsvwnln | Ntwqxxk | $12.2 Bil |